Combination immunotherapy of a novel superagonist IL-15 complex and anti-CD20 antibody for indolent non-hodgkin lymphoma
Ended Cooperative Agreement Awarded Last action
- Award ID
- R44CA195812
- Recipient
-
Altor Bioscience, LLC UEI MNK5L65P4L94
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,893,761
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Hollywood, FL 33025, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$34,350 | |
| Amendment | $966,343 | |
| Original award | $961,768 |
Quick answers
Who received award R44CA195812?
R44CA195812 was awarded to Altor Bioscience, LLC by National Cancer Institute (National Institutes of Health) on September 30, 2015.
How much is award R44CA195812 worth?
$1,893,761 has been obligated on R44CA195812.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award